Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | SOD1 | P00441 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716120 | 0.83 | CA12 (0.52) | CA12CA1CA9 | |
| SCHEMBL874186 | 0.83 | EPAS1 (0.38) | — | |
| SCHEMBL15416416 | 0.83 | VEGFA (0.32) | — | |
| SCHEMBL622877 | 0.83 | ACHE (0.34) | — | |
| SCHEMBL4043764 | 0.83 | ALDH1A1 (0.50) | CYP1A2CYP2A6 | |
| SCHEMBL1128558 | 0.79 | SCN9A (0.35) | IDO1SOD1CES2 | |
| SCHEMBL3439551 | 0.78 | CA12 (0.39) | CA12CA1CA9IDO1SOD1 | |
| SCHEMBL4048298 | 0.78 | FGFR1 (0.40) | SOD1CYP1A2 | |
| SCHEMBL1584993 | 0.78 | EPAS1 (0.40) | — | |
| SCHEMBL170454 | 0.74 | NFE2L2 (0.41) | IDO1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228437-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-11 | — | — | US | claimed |
| CN-117529470-A | Method for producing pyrrolidine compounds | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | claimed |
| US-11495769-B2 | Inorganic light emitting diode and inorganic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2022-11-08 | — | — | US | claimed |
| US-20210167321-A1 | INORGANIC LIGHT EMITTING DIODE AND INORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2021-06-03 | — | — | US | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260008767-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| EP-3909964-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2025-10-08 | — | — | EP | disclosed |
| EP-4608808-A1 | SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF | Basecamp Bio Inc. (KY) | 2025-09-03 | — | — | EP | disclosed |
| EP-4043500-B1 | ETHYLENE·ALPHA-OLEFIN·NON-CONJUGATED POLYENE COPOLYMER, USE THEREOF, AND MANUFACTURING METHOD THEREOF | MITSUI CHEMICALS INC (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-6667319-B2 | Benzyl-cyclohexyl-uredo-p-piperidinyl amido- or sulfamido-derivatives; obesity, metabolic disorders, eating disorders | SCHERING-PLOUGH CORPORATION | 2003-12-23 | — | — | US | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030207860-A1 | Neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION | 2003-11-06 | — | — | US | disclosed |
| US-6593493-B1 | 2-(Carboxy(unsaturated)alkyl)-1-(haloalkoxy)benzene derivatives; retinoid X receptors; cardiovascular, skin, eating and vision disorders; anticarcinogenic agents; non-insulin-dependent diabetes | LIGAND PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| WO-2003009845-A1 | SUBSTITUTED UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-02-06 | — | — | WO | disclosed |
| EP-1216221-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2001019770-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | CA12 3465/4885CA1 1448/4885CA9 2946/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | CA12 1457/4885CA1 976/4885CA9 732/4885 |
| US-20240228437-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | PAH, SPR, IL4I1 | CA12 2941/4885CA1 3104/4885CA9 604/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | CA12 522/4885CA1 701/4885CA9 339/4885 |
| US-20030207860-A1 | Neuropeptide Y Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | CA12 4142/4885CA1 4216/4885CA9 2146/4885 |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, GLP1R | CA12 1927/4885CA1 2253/4885CA9 1314/4885 |
| US-20260008767-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR3, SSTR2 | CA12 256/4885CA1 260/4885CA9 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.